NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News $81.40 +1.68 (+2.11%) As of 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsBuy This Stock About SPDR S&P Biotech ETF (NYSEARCA:XBI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SPDR S&P Biotech ETF alerts:Sign Up Key Stats Today's Range$79.33▼$81.7050-Day Range$69.80▼$88.8252-Week Range$66.66▼$105.47Volume13.96 million shsAverage Volume9.18 million shsMarket Capitalization$5.13 billionAssets Under Management$4.88 billionDividend Yield0.17%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF OverviewSPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More… SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.57%0.57%0.52%0.53%Other Expenses0.00%0.30%0.48%0.56%0.51%Total Expense0.35%0.70%0.72%0.73%0.71%Fee Waiver0.00%-0.45%-0.49%-0.65%-0.54%Net Expense0.35%0.61%0.63%0.58%0.60% Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address XBI ETF News HeadlinesZacks Investment Ideas feature highlights: Alibaba, JD.com, SPDR S&P Biotech ETF, Merck and MicrosoftMay 14, 2025 | msn.comXBI: Some Tariff Relief Right Now, But Macro Risks Remain In BiotechMay 13, 2025 | seekingalpha.comWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.May 20, 2025 | Priority Gold (Ad)Optimism is Back for Biotech Stocks. This Time, It Could Last.May 5, 2025 | msn.comSPDR S&P Biotech ETF Experiences Big InflowApril 16, 2025 | nasdaq.comFriday's ETF Movers: XBI, COPXMarch 23, 2025 | nasdaq.comSee More Headlines XBI ETF - Frequently Asked Questions How have XBI shares performed this year? SPDR S&P Biotech ETF's stock was trading at $90.06 at the beginning of the year. Since then, XBI stock has decreased by 9.6% and is now trading at $81.40. View the best growth stocks for 2025 here. Who are SPDR S&P Biotech ETF's major shareholders? SPDR S&P Biotech ETF's top institutional shareholders include Goldman Sachs Group Inc. (21.29%), JPMorgan Chase & Co. (16.32%), Jane Street Group LLC and Demars Financial Group LLC (4.94%). How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM). Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings153 Fund Statistics Assets Under Management$4.88 billion Average Daily Volume$12.49 million Discount/Premium-0.02% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume18,273 Put Options10,374 Call Options7,899 Short Interest72,740,000 shs Miscellaneous Outstanding Shares63,000,000Beta0.91 Creation Unit50,000 Creation Fee$250.00 10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report Top 10 XBI HoldingsExact Sciences (NASDAQ:EXAS)Holding Weight: 3.04%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 2.94%Neurocrine Biosciences (NASDAQ:NBIX)Holding Weight: 2.92%Natera (NASDAQ:NTRA)Holding Weight: 2.88%United Therapeutics (NASDAQ:UTHR)Holding Weight: 2.67%Blueprint Medicines (NASDAQ:BPMC)Holding Weight: 2.44%Insmed (NASDAQ:INSM)Holding Weight: 2.42%Gilead Sciences (NASDAQ:GILD)Holding Weight: 2.41%AbbVie (NYSE:ABBV)Holding Weight: 2.37%Incyte (NASDAQ:INCY)Holding Weight: 2.37%Full Holdings DetailsXBI Sector ExposureXBI Industry Exposure This page (NYSEARCA:XBI) was last updated on 5/20/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredHow I profit during chaos…This Guy THRIVES on Chaos Wall Street legend Larry Benedict has thrived through every major market crash. I...Brownstone Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.